Emerging strategies to target RAS signaling in human cancer therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34301278/
RAS mutations (HRAS, NRAS, and KRAS) are among the most common oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring RAS mutations tend to undergo malignant...
Lentiviral-driven discovery of cancer drug resistance mutations - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34301758/
Identifying resistance mutations in a drug target provides crucial information. Lentiviral transduction creates multiple types of mutations due to the error-prone nature of the HIV-1 reverse transcriptase (RT). Here we...
Stopping the beating heart of cancer: KRAS reviewed - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34303932/
It has taken four decades of research to see the first major breakthrough for KRAS-driven cancers. In particular, the last decade has seen a paradigm shift with the discovery of...
Spotlight on KRAS G12C: Biomarker Testing Considerations in the NSCLC Landscape
/>
Spotlight on KRAS G12C: Biomarker Testing Considerations in the NSCLC Landscape
In the current era of cancer care, we've come to realize that non-small cell lung cancer is a disease of the genome. And now that advances in genomic profiling have...
LabCorp launches KRAS mutation analysis for new lung cancer therapy
LabCorp launches diagnostic for new lung cancer therapy | WRAL TechWire
Editor's note: LimeLight is a new feature from WRAL TechWire offering another means of publishing noteworthy news. Be sure to check out more LimeLight worthy news at this link. BURLINGTON...